JP2009539938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539938A5 JP2009539938A5 JP2009514801A JP2009514801A JP2009539938A5 JP 2009539938 A5 JP2009539938 A5 JP 2009539938A5 JP 2009514801 A JP2009514801 A JP 2009514801A JP 2009514801 A JP2009514801 A JP 2009514801A JP 2009539938 A5 JP2009539938 A5 JP 2009539938A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- piperidinecarboxamide
- piperazinyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- VAHGCBIEHWKWMD-IBGZPJMESA-N 4-(3-fluoroanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(F)C=CC=2)C=C1 VAHGCBIEHWKWMD-IBGZPJMESA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- -1 (piperazinyl) methylene substituent Chemical group 0.000 claims 1
- AEMCAHYRZPQHGI-IBGZPJMESA-N 4-(2-carbamoylanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C(=CC=CC=2)C(N)=O)C=C1 AEMCAHYRZPQHGI-IBGZPJMESA-N 0.000 claims 1
- NOOCUGDSASZTIW-FQEVSTJZSA-N 4-(2-cyanoanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C(=CC=CC=2)C#N)C=C1 NOOCUGDSASZTIW-FQEVSTJZSA-N 0.000 claims 1
- RVEDDKMAENNWSJ-IBGZPJMESA-N 4-(2-fluoroanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C(=CC=CC=2)F)C=C1 RVEDDKMAENNWSJ-IBGZPJMESA-N 0.000 claims 1
- POTIXHFLOMRIPL-UHFFFAOYSA-N 4-(3-cyanoanilino)-N-methyl-N-[4-(piperazin-1-ylmethyl)phenyl]piperidine-1-carboxamide Chemical compound C=1C=C(CN2CCNCC2)C=CC=1N(C)C(=O)N(CC1)CCC1NC1=CC=CC(C#N)=C1 POTIXHFLOMRIPL-UHFFFAOYSA-N 0.000 claims 1
- YTEWUWUUWKZUEH-FQEVSTJZSA-N 4-(3-cyanoanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(C=CC=2)C#N)C=C1 YTEWUWUUWKZUEH-FQEVSTJZSA-N 0.000 claims 1
- CBGQNRZLQSNQNS-FQEVSTJZSA-N 4-(3-cyanophenyl)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)C=2C=C(C=CC=2)C#N)C=C1 CBGQNRZLQSNQNS-FQEVSTJZSA-N 0.000 claims 1
- WMSXCTMDOXKYEK-IBGZPJMESA-N 4-(3-fluoro-4-methoxyanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1NC1CCN(C(=O)N(C)C=2C=CC(CN3C[C@H](C)NCC3)=CC=2)CC1 WMSXCTMDOXKYEK-IBGZPJMESA-N 0.000 claims 1
- UGSIGXWFIZZAAR-FQEVSTJZSA-N 4-(3-fluoroanilino)-N-methyl-N-[3-methyl-4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(F)C=CC=2)C=C1C UGSIGXWFIZZAAR-FQEVSTJZSA-N 0.000 claims 1
- GBDNMGFJZHEWJK-UHFFFAOYSA-N 4-(3-fluoroanilino)-N-methyl-N-[4-(piperazin-1-ylmethyl)phenyl]piperidine-1-carboxamide Chemical compound C=1C=C(CN2CCNCC2)C=CC=1N(C)C(=O)N(CC1)CCC1NC1=CC=CC(F)=C1 GBDNMGFJZHEWJK-UHFFFAOYSA-N 0.000 claims 1
- VAHGCBIEHWKWMD-LJQANCHMSA-N 4-(3-fluoroanilino)-N-methyl-N-[4-[[(3R)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(F)C=CC=2)C=C1 VAHGCBIEHWKWMD-LJQANCHMSA-N 0.000 claims 1
- QEJHPRPCSRIROF-SFHVURJKSA-N 4-(3-fluoroanilino)-N-methyl-N-[6-[[(3S)-3-methylpiperazin-1-yl]methyl]pyridin-3-yl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(F)C=CC=2)C=N1 QEJHPRPCSRIROF-SFHVURJKSA-N 0.000 claims 1
- MHWVNOWZAYMLBI-IBGZPJMESA-N 4-(3-fluorophenoxy)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)OC=2C=C(F)C=CC=2)C=C1 MHWVNOWZAYMLBI-IBGZPJMESA-N 0.000 claims 1
- ZMIHIMYJXRASEQ-IBGZPJMESA-N 4-(3-fluorophenyl)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)C=2C=C(F)C=CC=2)C=C1 ZMIHIMYJXRASEQ-IBGZPJMESA-N 0.000 claims 1
- VBSRCXCGKMBKIV-FQEVSTJZSA-N 4-(4-cyanoanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=CC(=CC=2)C#N)C=C1 VBSRCXCGKMBKIV-FQEVSTJZSA-N 0.000 claims 1
- FQQOBLHOKLMWSN-IBGZPJMESA-N 4-(4-fluoro-3-methoxyanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1=C(F)C(OC)=CC(NC2CCN(CC2)C(=O)N(C)C=2C=CC(CN3C[C@H](C)NCC3)=CC=2)=C1 FQQOBLHOKLMWSN-IBGZPJMESA-N 0.000 claims 1
- PDPFEGLNWDJQTL-UHFFFAOYSA-N 4-(4-fluoroanilino)-N-methyl-N-[4-(piperazin-1-ylmethyl)phenyl]piperidine-1-carboxamide Chemical compound C=1C=C(CN2CCNCC2)C=CC=1N(C)C(=O)N(CC1)CCC1NC1=CC=C(F)C=C1 PDPFEGLNWDJQTL-UHFFFAOYSA-N 0.000 claims 1
- OKKIPMUUMQAQDL-IBGZPJMESA-N 4-(4-fluoroanilino)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=CC(F)=CC=2)C=C1 OKKIPMUUMQAQDL-IBGZPJMESA-N 0.000 claims 1
- OJJXMMVVELBULF-IBGZPJMESA-N 4-(4-fluorophenyl)-N-methyl-N-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]piperidine-1-carboxamide Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)C=2C=CC(F)=CC=2)C=C1 OJJXMMVVELBULF-IBGZPJMESA-N 0.000 claims 1
- LOZWNVRRUMVRHD-BGYRXZFFSA-N N-[4-[[(3S,5R)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(3-fluoroanilino)-N-methylpiperidine-1-carboxamide Chemical compound C1[C@@H](C)N[C@@H](C)CN1CC1=CC=C(N(C)C(=O)N2CCC(CC2)NC=2C=C(F)C=CC=2)C=C1 LOZWNVRRUMVRHD-BGYRXZFFSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 0 CN1C(*)CN(C/C2=C\C=C\C(\N(*)C(N3CCC(**)CC3)=O)=C/C=C2)CC1* Chemical compound CN1C(*)CN(C/C2=C\C=C\C(\N(*)C(N3CCC(**)CC3)=O)=C/C=C2)CC1* 0.000 description 1
Description
[式中:
Aは、ハロゲン、C(1−4)アルキルまたはC(1−4)アルコキシで置換されていてもよいフェニルまたは6員のヘテロアリール環であり;
R1およびR2は、独立して、HまたはC(1−4)アルキルであり;
R3は、置換されていてもよいフェニルまたは置換されていてもよい5もしくは6員のヘテロアリールであり;
Yは、NH、O、CH2または結合であり;
R4は、C(1−4)アルキルまたはC(1−4)アルコキシC(1−4)アルキルである]
で示される化合物またはその医薬上許容される塩または誘導体を提供する。
Aは、ハロゲン、C(1−4)アルキルまたはC(1−4)アルコキシで置換されていてもよいフェニルまたは6員のヘテロアリール環であり;
R1およびR2は、独立して、HまたはC(1−4)アルキルであり;
R3は、置換されていてもよいフェニルまたは置換されていてもよい5もしくは6員のヘテロアリールであり;
Yは、NH、O、CH2または結合であり;
R4は、C(1−4)アルキルまたはC(1−4)アルコキシC(1−4)アルキルである]
で示される化合物またはその医薬上許容される塩または誘導体を提供する。
Claims (8)
- Aがフェニルまたはピリジルであり;および/または
R1が水素またはメチルであり;および/または
R2が水素またはメチルであり;および/または
R3が置換されていてもよいフェニルであり;および/または
YがNH、Oまたは結合であり;および/または
R4がメチルである、請求項1記載の式(I)の化合物またはその医薬上許容される塩。 - (ピペラジニル)メチレン置換基および−NR4が環Aを挟んで互いにパラ位にある請求項1または2記載の化合物またはその塩。
- 4−[(3−フルオロフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(4−フルオロフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(3−シアノフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(2−フルオロフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(4−シアノフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−{[2−(アミノカルボニル)フェニル]アミノ}−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(3−フルオロフェニル)オキシ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(2−シアノフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−{[3−フルオロ−4−(メチルオキシ)フェニル]アミノ}−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−{[4−フルオロ−3−(メチルオキシ)フェニル]アミノ}−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(3−フルオロフェニル)アミノ]−N−メチル−N−(4−{[(3R)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
N−(4−{[(3R,5S)−3,5−ジメチル−1−ピペラジニル]メチル}フェニル)−4−[(3−フルオロフェニル)アミノ]−N−メチル−1−ピペリジンカルボキサミド、
4−[(3−シアノフェニル)アミノ]−N−メチル−N−[4−(1−ピペラジニルメチル)フェニル]−1−ピペリジンカルボキサミド、
4−[(3−フルオロフェニル)アミノ]−N−メチル−N−[4−(1−ピペラジニルメチル)フェニル]−1−ピペリジンカルボキサミド、
4−[(4−フルオロフェニル)アミノ]−N−メチル−N−[4−(1−ピペラジニルメチル)フェニル]−1−ピペリジンカルボキサミド、
4−(4−フルオロフェニル)−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−(3−フルオロフェニル)−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−(3−シアノフェニル)−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(3−フルオロフェニル)アミノ]−N−メチル−N−(3−メチル−4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミド、
4−[(3−フルオロフェニル)アミノ]−N−メチル−N−(6−{[(3S)−3−メチル−1−ピペラジニル]メチル}−3−ピリジニル)−1−ピペリジンカルボキサミド
から選択される化合物またはその塩。 - 4−[(3−フルオロフェニル)アミノ]−N−メチル−N−(4−{[(3S)−3−メチル−1−ピペラジニル]メチル}フェニル)−1−ピペリジンカルボキサミドである、請求項1記載の式(I)の化合物またはその塩。
- Aが置換されていてもよいフェニルまたは置換されていてもよいピリジルであるときの請求項1〜5のいずれか1項記載の化合物またはその医薬上許容される塩:
(a)式(II):
で示される化合物および式(III):
で示される化合物を、尿素形成に適当な反応条件を用いて、反応させ、
(b)その後、下記の反応:
いずれかの保護基の除去;
かくして形成された化合物の適当な医薬上許容される塩または溶媒和物の形成
の1以上を行ってもよい
ことを特徴とする製法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0611907.7 | 2006-06-15 | ||
GBGB0611907.7A GB0611907D0 (en) | 2006-06-15 | 2006-06-15 | Compounds |
PCT/EP2007/055890 WO2007144400A1 (en) | 2006-06-15 | 2007-06-14 | Benzylpiperazine derivatives as motilin receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009539938A JP2009539938A (ja) | 2009-11-19 |
JP2009539938A5 true JP2009539938A5 (ja) | 2013-03-21 |
JP5232143B2 JP5232143B2 (ja) | 2013-07-10 |
Family
ID=36775731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009514801A Expired - Fee Related JP5232143B2 (ja) | 2006-06-15 | 2007-06-14 | モチリン受容体アンタゴニストとしてのベンジルピペラジン誘導体 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8012981B2 (ja) |
EP (1) | EP2029538B1 (ja) |
JP (1) | JP5232143B2 (ja) |
AT (1) | ATE542795T1 (ja) |
ES (1) | ES2379658T3 (ja) |
GB (1) | GB0611907D0 (ja) |
WO (1) | WO2007144400A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0611907D0 (en) * | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
US8536182B2 (en) | 2005-07-26 | 2013-09-17 | Glaxo Group Limited | Benzylpiperazine derivatives and their medical use |
GB0524814D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US8494661B2 (en) | 2007-12-28 | 2013-07-23 | Server Technology, Inc. | Power distribution, management, and monitoring systems and methods |
JP5028484B2 (ja) | 2006-06-28 | 2012-09-19 | グラクソ グループ リミテッド | Gpr38受容体媒介疾患の治療に有用なピペラジニル誘導体 |
US8321163B2 (en) | 2009-03-04 | 2012-11-27 | Server Technology, Inc. | Monitoring power-related parameters in a power distribution unit |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
CN103209696B (zh) | 2010-04-21 | 2016-02-24 | 文蒂雷克斯药品公司 | 增强抗体依赖性细胞的细胞毒性的方法 |
NZ609596A (en) | 2010-09-27 | 2013-12-20 | Daiichi Sankyo Co Ltd | Cyclohexane derivative compound |
WO2012109267A2 (en) | 2011-02-07 | 2012-08-16 | The Trustees Of The University Of Pennsylvania | Novel peptides and methods using same |
WO2017157873A1 (en) | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
US5385912A (en) * | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
JPH06211886A (ja) | 1992-11-04 | 1994-08-02 | Chugai Pharmaceut Co Ltd | エリスロマイシン誘導体 |
TW355711B (en) | 1992-11-04 | 1999-04-11 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives |
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
JP3901239B2 (ja) | 1996-03-13 | 2007-04-04 | 大正製薬株式会社 | アリールアルカン誘導体 |
US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU717190B2 (en) | 1996-04-03 | 2000-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DE19644195A1 (de) * | 1996-10-24 | 1998-04-30 | Solvay Pharm Gmbh | 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6100239A (en) * | 1996-11-26 | 2000-08-08 | Chugai Seiyaku Kabushiki Kaisha | 13-membered ring macrolide compound, medicine containing the same, and process for producing the same |
US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
US5972939A (en) * | 1997-10-28 | 1999-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclopentene derivatives useful as antagonists of the motilin receptor |
US6165985A (en) * | 1998-02-13 | 2000-12-26 | Solvay Pharmaceuticals Gmbh | 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them |
DE19805822B4 (de) | 1998-02-13 | 2009-02-05 | Solvay Pharmaceuticals Gmbh | 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
GB9804734D0 (en) * | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
US20020052380A1 (en) * | 2000-02-18 | 2002-05-02 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
US20020010184A1 (en) | 2000-02-18 | 2002-01-24 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
AU2001247357A1 (en) * | 2000-03-13 | 2001-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclobutene derivatives useful as antagonists of the motilin receptor |
US6423714B2 (en) * | 2000-03-13 | 2002-07-23 | Ortho Mcneil-Pharmaceutical, Inc.. | Cyclohexene derivatives useful as antagonists of the motilin receptor |
WO2001068620A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclopentene derivatives useful as antagonists of the motilin receptor |
US6511980B2 (en) * | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
EP1392679B1 (de) * | 2001-05-10 | 2005-11-02 | Solvay Pharmaceuticals GmbH | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
CA2504272A1 (en) | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
US7223788B2 (en) * | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
US7262195B2 (en) * | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
US7338954B2 (en) * | 2003-09-17 | 2008-03-04 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
JPWO2005063720A1 (ja) | 2003-12-25 | 2007-07-19 | 日本新薬株式会社 | アミド誘導体及び医薬 |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050277629A1 (en) * | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
SE0401970D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Novel compounds |
GB0611907D0 (en) * | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
JP2009501199A (ja) | 2005-07-12 | 2009-01-15 | グラクソ グループ リミテッド | Gpr38アゴニストとしてのピペラジンヘテロアリール誘導体 |
US8536182B2 (en) * | 2005-07-26 | 2013-09-17 | Glaxo Group Limited | Benzylpiperazine derivatives and their medical use |
GB0524814D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
JP5028484B2 (ja) * | 2006-06-28 | 2012-09-19 | グラクソ グループ リミテッド | Gpr38受容体媒介疾患の治療に有用なピペラジニル誘導体 |
GB0723317D0 (en) * | 2007-11-28 | 2008-01-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-06-15 GB GBGB0611907.7A patent/GB0611907D0/en not_active Ceased
-
2007
- 2007-06-14 US US12/304,539 patent/US8012981B2/en not_active Expired - Fee Related
- 2007-06-14 ES ES07765418T patent/ES2379658T3/es active Active
- 2007-06-14 EP EP07765418A patent/EP2029538B1/en active Active
- 2007-06-14 WO PCT/EP2007/055890 patent/WO2007144400A1/en active Application Filing
- 2007-06-14 AT AT07765418T patent/ATE542795T1/de active
- 2007-06-14 JP JP2009514801A patent/JP5232143B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-20 US US13/186,869 patent/US8236953B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009539938A5 (ja) | ||
JP2008519814A5 (ja) | ||
RU2489148C2 (ru) | Ингибитор активации stat3/5 | |
HRP20120833T1 (hr) | Derivati benzilpiperazina, korisni u lijeäśenju gastrointestinalnih poremeä†aja | |
RU2336267C2 (ru) | Производные пирролидона в качестве ингибиторов маов | |
NZ520041A (en) | Novel piperidine compounds and drugs containing the same | |
HUP0103988A2 (en) | New d3-dopamine receptor selective piperazine and piperidine compounds, process for their preparation, their and pharmaceutical compositions containing them | |
JP2010538076A5 (ja) | ||
EP1396487A1 (en) | Phenylpyridine carbonyl piperazine derivative | |
JP2004518725A5 (ja) | ||
JP2015517981A5 (ja) | ||
RU2004119406A (ru) | 5-сульфанил-4н-1,2,4-триазольные производные и их применение в качестве лекарственного препарата | |
RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
JP2013525479A (ja) | ピコリンアミド及びピリミジン‐4‐カルボキサミド化合物、その製造方法及びそれを含む医薬組成物 | |
RU2010116765A (ru) | Никотинамидные производные, их получение и их применение в терапии | |
CA2476343A1 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
RU2007148217A (ru) | Получение производных n-фенил-2-пиримидинамина | |
EP0661266A1 (en) | Substituted cyclic amine compounds as 5HT2 antagonists | |
JP2010504930A5 (ja) | ||
HRP20151336T1 (hr) | Tetrahidroizokinolin-1-on derivat ili njegova sol | |
WO2000009483A3 (en) | Process and intermediates for production of donepezil and related compounds | |
HRP20100284T1 (hr) | Derivati piperazinila korisni u liječenju bolesti posredovanih receptorom gpr38 | |
RU98117621A (ru) | Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт | |
CA2461963C (en) | Cyclic amine compounds | |
JPS62192359A (ja) | 1,4−ジヒドロピリジン化合物の製法 |